In order to test, whether Ucma may consequently be a candidate for the treatment of arthritis-triggered cartilage damage in vivo, we investigated SIA-triggered cartilage degradation in C57/Bl6 mice systemically treated with recombinant Ucma. This evidence concerns the gene UCMA and arthritic joint disease.